Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term tyrosine kinase inhibitor. Found 20 abstracts

Nemunaitis J, Bauer S, Blay JY, Choucair K, Gelderblom H, George S, Schoffski P, Mehren MV, Zalcberg J, Achour H, Ruiz-Soto R, Heinrich MC. Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. Future Oncol. 2020 Jan;16(1):4251-64.
Cukierman E, Bassi DE. The mesenchymal tumor microenvironment A drug-resistant niche. Cell Adhesion & Migration. 2012 May;6(3):285-96.   PMCID: PMC3427243
von Mehren M, Rankin C, Goldblum JR, Demetri GD, Bramwell V, Ryan CW, Borden E. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer. 2012 Feb;118(3):770-6.   PMCID: PMC3576704
Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecologic Oncology. 2011 Apr;121(1):230-8.   PMCID: not NIH funded
Gupta S, Engstrom PF, Cohen SJ. Emerging Therapies for Advanced Gastroenteropancreatic Neuroendocrine Tumors. Clinical Colorectal Cancer. 2011 Dec;10(4):298-309.   PMCID: NIHMS329029
Heath EI, Blumenschein GR, Cohen RB, LoRusso PM, LoConte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemotherapy and Pharmacology. 2011 Sep;68(3):703-12.   PMCID: not NIH funded
Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biology & Therapy. 2010 Oct;10(7):658-64.   PMCID: PMC3093809
Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song LX, Rawal B, Schell MJ, Bepler G. Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. 2010 Mar;28(8):1387-94.   PMCID: PMC3040065
Figlin RA, de Souza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Boni J, Hudes G. Analysis of PTEN and HIF-1 alpha and Correlation With Efficacy in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus Versus Interferon-alpha. Cancer. 2009 Aug;115(16):3651-60.   PMCID: not NIH funded
Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opinion on Therapeutic Targets. 2009 Mar;13(3):339-62.   PMCID: PMC2670612
O'Brien S, Berman E, Borghaei H, DeAngelo DJ, Devetten MP, Devine S, Erba HP, Gotlib J, Jagasia M, Moore JO, Mughal T, Radich JP, Shah NP, Smith BD, Snyder DS, Talpaz M, Wetzler M. Chronic Myelogenous Leukemia. Journal of the National Comprehensive Cancer Network. 2009 Oct;7(9):984-1023.   PMCID: not NIH funded
Cohen RB, Langer CJ, Simon GR, Eisenberg PD, Hainsworth JD, Madajewicz S, Cosgriff TM, Pierce K, Xu H, Liau K, Healey D. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). Cancer Chemotherapy and Pharmacology. 2007 Jun;60(1):81-9.
Liu H, Cheng D, Weichel AK, Osipo C, Wing LK, Chen B, Louis TE, Jordan VC. Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells. INTERNATIONAL JOURNAL OF ONCOLOGY. 2006 Nov;29(5):1237-46.
Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology. 2006 Jan;24(1):16-24.
Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. Sunitinib in patients with metastatic renal cell carcinoma. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2006 Jun;295(21):2516-24.
Cohen SJ, Cohen RB, Meropol NJ. Targeting signal transduction pathways in colorectal cancer - More than skin deep. Journal of Clinical Oncology. 2005 Aug 10;23(23):5374-85.
von Mehren M, Watson JC. Gastrointestinal stromal tumors. Hematology-Oncology Clinics of North America. 2005 Jun;19(3):547-+.
Peterson JR, Golemis EA. Autoinhibited proteins as promising drug targets. Journal of cellular biochemistry. 2004 Sep;93(1):68-73.
Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R, Haas N, Lockbaum P, Li YP, Arends R, Foon KA, Schwab G, Dutcher J. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. Journal of Clinical Oncology. 2004 Aug;22(15):3003-15.
Cohen SJ, Meropol NJ. Drug development in pancreatic cancer - Finally, biology begets therapy. International Journal of Gastrointestinal Cancer. 2002 Jan;32(2-3):91-106.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term tyrosine kinase inhibitor

tyrosine kinase inhibitor growth-factor therapy antitumor-activity growth-factor receptor EGFR targeted therapy in-vivo chronic myeloid-leukemia imatinib mesylate lung-cancer endothelial growth-factor gene-expression expression factor receptor interleukin-2 NSCLC chemotherapy prognostic-factors interferon phase-ii trial phase-i trial endothelial vaccines imatinib acute lymphoblastic-leukemia autoinhibition of-function mutations advanced colorectal-cancer human-breast-cancer protein regulation Her-2 RCC grade activation mtor inhibitor fulvestrant-resistance interferon-alpha ANGIOGENESIS kidney cancer multiple-myeloma cells target selection BREAST-CANCER donor lymphocyte infusions cetuximab mutations ABC transporter beta-subunit tumor-stromal interactions tumor microenvironment-stromal-induced drug resistance-extracellular matrix-tumor-associated or carcinoma-associated fibroblasts-matrix-induced drug resistance-mesenchymal stroma progression 1994 audhry a-anticancer research-v14-p2085 protooncogene platinum-resistant colony-stimulating factor triple angiokinase inhibitor pancreatic-cancer phase-ii growth zd1839 iressa pancreatic cancer therapies adhesion-mediated drug somatostatin 2008 iorean eg-v26-p2008 c-abl randomized-trial stem-cell transplantation multidrug-resistance tumor-suppressor gene phase I hypoxia-inducible factor-1 leukemia malignant carcinoid-syndrome family kinase bone-marrow microenvironment VEGF receptor tyrosine kinase phase-iii trial apoptosis-inducing ligand hemangiopericytoma PROGRESSION experience metabolism lines resistant signaling pathways carboplatin angiosarcoma matrix metalloproteinase inhibitors Sunitinib family kinases Oncology Antiangiogenesis Pdgfra factor-kappa-b Dcc-2618 breast-cancer cells pathway 1992 audhry a-cancer research-v52-p1006 SURVIVAL Targeted therapy structural basis Neuroendocrine tumors fibroblast-growth-factor Ovarian cancer 1993 audhry a-acta oncologica-v32-p107 allogenic HSCT NETWORK Chemotherapy polymerase-chain-reaction ripretinib su11248 VEGFR-2 Kit ACUTE MYELOID-LEUKEMIA response CELL LUNG-CANCER monoclonal-antibody enhanced antitumor-activity PHASE-III TRIAL TYROSINE KINASE INHIBITORS drug-resistance signal-transduction pathway transplantation colon-cancer cell kinases c-kit liposarcoma sunitinib vhl METASTATIC COLORECTAL-CANCER 1995 ristofori g-molecular endocrinology-v9-p1760 complete cytogenetic mammalian target soft-tissue sarcomas cell lung-cancer PROTEIN-INTERACTION complex breast cancer epigenetics AGENT erlotinib FTI resistance General & Internal Medicine Anti-angiogenic therapy transporter abcg2 angiogenesis in-vitro
Last updated on Wednesday, February 05, 2020